The Food and Drug Administration (FDA) has announced that it is requiring manufacturers to put a boxed warning on the prescribing information for the smoking cessation drugs Chantix and Zyban.
The Food and Drug Administration (FDA) has announced that it is requiring manufacturers to put a boxed warning on the prescribing information for the smoking cessation drugs Chantix and Zyban. The warning will highlight the risk of serious mental health events, including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.
“The risk of serious adverse events while taking these products must be weighed against the significant health benefits of quitting smoking,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research. “Smoking is the leading cause of preventable disease, disability, and death in the United States and we know these products are effective aids in helping people quit.”
Similar information on mental health events will be required for buproprion marketed as the antidepressant Wellbutrin and for generic versions of buproprion. These drugs already carry a boxed warning for suicidal behavior in treating psychiatric disorders.
The FDA’s request for the additional warnings is based on a review of reports submitted to the agency’s Adverse Event Reporting System since the time the products were marketed and on an analysis of information from clinical trials and scientific literature.
The analyses showed that some people who have taken Chantix and Zyban have reported experiencing unusual changes in behavior, become depressed, or had their depression worsen, and had thoughts of suicide or dying. In many cases, the problems started soon after starting the medication and ended when the medication was stopped. However, some people continued to have symptoms after stopping the medication. Also, in a few cases, the problems began after the medication was stopped.
In addition to the boxed warning, the FDA also is requesting more information in the warnings section of the prescribing information and updated information in the Medication Guide for patients that further discuss the risk of mental health events when using these products.
Manufacturers also will be required to conduct a clinical trial to determine how often serious neuropsychiatric symptoms occur in patients using various smoking cessation therapies, including patients who currently have psychiatric disorders.
The FDA said its review of adverse events for patients using nicotine patches did not identify a clear link between those medications and suicidal events.